The SURMOUNT-2 Trial: Tirzepatide in Type 2 Diabetes
TRIAL-000015
Part of the DietApp.com GLP-1 Trial Database, a comprehensive, regularly reviewed resource.
What It Is
SURMOUNT-2 tested tirzepatide's weight-loss effect specifically in adults with obesity or overweight who also have type 2 diabetes, a population studied separately from SURMOUNT-1, which excluded participants with diabetes.
Key Results
SURMOUNT-2 showed mean weight reduction of up to approximately 15.7% in participants with type 2 diabetes, compared to up to 22.5% in the non-diabetes SURMOUNT-1 population at a comparable dose and duration. This gap is a well-documented, expected pattern, not unique to tirzepatide, GLP-1 weight-loss trials consistently show somewhat lower average weight loss in participants with type 2 diabetes than in those without.
Why People With Diabetes See Somewhat Less Weight Loss
The leading explanation isn't that the medication works less well in people with diabetes, it's tied to underlying metabolic differences, including insulin resistance patterns, that are common in type 2 diabetes and can influence weight-loss response to any intervention, not specific to GLP-1 medications alone.
Why This Distinction Matters for You
If you have type 2 diabetes and are comparing your own weight-loss results against headline trial numbers you've seen for Zepbound, SURMOUNT-2's figures, not SURMOUNT-1's, are the more relevant comparison for your situation.
References
- PMC: Tirzepatide for the Treatment of Obstructive Sleep Apnea, SURMOUNT-OSA Trial Design (background on SURMOUNT-1 and SURMOUNT-2 comparative results)
Related Resources
Related Articles
How SURMOUNT-2 Fits Into the Full SURMOUNT Program
| Trial | Population | Real Weight Loss Result |
|---|---|---|
| SURMOUNT-1 | Obesity, no diabetes | Up to ~22.5% |
| SURMOUNT-2 | Obesity with type 2 diabetes | Up to ~15.7% |
| SURMOUNT-4 | Post-treatment discontinuation | Real regain data, see dedicated page |
| SURMOUNT-OSA | Obesity with sleep apnea | Real AHI reduction, see dedicated page |
See DietApp's main SURMOUNT Trials page for the complete program overview, SURMOUNT-4 for what happens after stopping treatment, and SURMOUNT-OSA for the sleep apnea-specific findings.
Frequently Asked Questions
Does 15.7% mean tirzepatide works worse for people with diabetes? No, this is a real, well-documented, expected pattern across the entire GLP-1 class, not a tirzepatide-specific weakness.
Which SURMOUNT trial applies to me if I have diabetes? SURMOUNT-2's figures are the more relevant, real comparison point, not SURMOUNT-1's headline numbers.
Can weight loss improve further with a longer diabetes treatment duration? Individual results vary meaningfully; discuss your specific trajectory directly with your provider.
Explore More
Explore the full GLP-1 Tracker knowledge base on DietApp.com
Get Started
Download DietApp.com to track your own progress alongside the evidence behind your treatment.
About DietApp.com
DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. The information on DietApp.com is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.
Last medically reviewed and updated: July 11, 2026.
surmount-2-trial-tirzepatide-diabetes